A 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study

Abstract ▪3212▪This icon denotes a clinically relevant abstract Children with sickle cell disease (SCD) have a significantly increased risk of invasive pneumococcal disease (IPD) and mortality, primarily attributable to functional asplenia. Penicillin prophylaxis and PPSV23 have been shown to dramat...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2012-11, Vol.120 (21), p.3212-3212
Main Authors: De Montalembert, Mariane, Abboud, Miguel R., Fiquet, Anne, Inati, Adlette, Lebensburger, Jeffrey D., Kaddah, Normeen, Piga, Antonio, Inusa, Baba, Jiang, Qin, Pereira, Lisa, Emini, Emilio A., Gruber, William C., Gurtman, Alejandra, Scott, Daniel A.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract ▪3212▪This icon denotes a clinically relevant abstract Children with sickle cell disease (SCD) have a significantly increased risk of invasive pneumococcal disease (IPD) and mortality, primarily attributable to functional asplenia. Penicillin prophylaxis and PPSV23 have been shown to dramatically reduce those risks, but strain resistance to penicillin has increased. Furthermore, PPSV23 is less effective in children
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V120.21.3212.3212